Prostate Cancer in Patients with Metabolic Syndrome Is Associated with Low Grade Gleason Score When Diagnosed on Biopsy

다국어 초록 (Multilingual Abstract)

Purpose: Studies on the relationship of metabolic syndrome (MS) and prostate cancer are controversial. We evaluated the association between MS and prostate cancer characteristics in patients who underwent transrectal ultrasound-guided prostate biopsy.
Materials and Methods: From October 2003 to May 2011, patients with a prostate-specific antigen (PSA) value≥4 ng/ml or abnormal digital rectal examination (DRE) result underwent transrectal ultrasound-guided prostate biopsy. MS was diagnosed according to the Adult Treatment Panel III. Clinicopathologic factors including PSA, DRE, prostate volume, age, waist circumference, body mass index (BMI), lipid profiles, fasting blood sugar level, and MS were considered for analysis.
Results: Three hundred fifty-four patients were enrolled (mean age, 68.86±8.95 years; mean PSA, 13.97±20.42 ng/ml). Seventy-five patients (21.2%) had MS and 90 patients (25.4%) were diagnosed as having prostate cancer, including 27 (30%) with MS and 63 (70%) without MS. Total PSA value and prostate volume were significant predictors for prostate cancer. However, MS and BMI were not significantly related to increased cancer risk. Prostate cancer patients with MS had significantly lower Gleason scores (average, 6.63±1.92) than did prostate cancer patients without MS (average, 7.54±1.71; p=0.029).
Conclusions: Presence of MS was associated with a significantly decreased risk of high-grade prostate cancer. A larger, prospective, multicenter investigation is mandatory to clarify the relationship between MS and prostate cancer.

다국어 초록 (Multilingual Abstract)

Purpose: Studies on the relationship of metabolic syndrome (MS) and prostate cancer are controversial. We evaluated the association between MS and prostate cancer characteristics in patients who underwent transrectal ultrasound-guided prostate biopsy.
Materials and Methods: From October 2003 to May 2011, patients with a prostate-specific antigen (PSA) value≥4 ng/ml or abnormal digital rectal examination (DRE) result underwent transrectal ultrasound-guided prostate biopsy. MS was diagnosed according to the Adult Treatment Panel III. Clinicopathologic factors including PSA, DRE, prostate volume, age, waist circumference, body mass index (BMI), lipid profiles, fasting blood sugar level, and MS were considered for analysis.
Results: Three hundred fifty-four patients were enrolled (mean age, 68.86±8.95 years; mean PSA, 13.97±20.42 ng/ml). Seventy-five patients (21.2%) had MS and 90 patients (25.4%) were diagnosed as having prostate cancer, including 27 (30%) with MS and 63 (70%) without MS. Total PSA value and prostate volume were significant predictors for prostate cancer. However, MS and BMI were not significantly related to increased cancer risk. Prostate cancer patients with MS had significantly lower Gleason scores (average, 6.63±1.92) than did prostate cancer patients without MS (average, 7.54±1.71; p=0.029).
Conclusions: Presence of MS was associated with a significantly decreased risk of high-grade prostate cancer. A larger, prospective, multicenter investigation is mandatory to clarify the relationship between MS and prostate cancer.

참고문헌 (Reference)

1 한병규, "대사증후군이 동반된 전립선암의 종양학적 특징" 대한비뇨기과학회 48 (48): 585-591, 2007

2 Tande AJ, "The metabolic syndrome is associated with reduced risk of prostate cancer" 164 : 1094-1102, 2006

3 LeRoith D, "The insulin-like growth factor system and cancer" 195 : 127-137, 2003

4 Khandwala HM, "The effects of insulin-like growth factors on tumorigenesis and neoplastic growth" 21 : 215-244, 2000

5 De Nunzio C, "The correlation between metabolic syndrome and prostatic diseases" 61 : 560-570, 2012

6 Moreira DM, "The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series" 22 : 977-983, 2011

7 Platz EA, "Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era" 14 : 1262-1269, 2005

8 Valko M, "Role of oxygen radicals in DNA damage and cancer incidence" 266 : 37-56, 2004

9 Barnard RJ, "Prostate cancer: another aspect of the insulin-resistance syndrome?" 3 : 303-308, 2002

10 Chung HW, "Prevalence of metabolic syndrome according to the new criteria for obesity" 26 : 431-442, 2002

11 Chan JM, "Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study" 279 : 563-566, 1998

12 Calle EE, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults" 348 : 1625-1638, 2003

13 Kirby MG, "Overactive bladder: Is there a link to the metabolic syndrome in men?" 29 : 1360-1364, 2010

14 Kaaks R, "Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review" 11 : 1531-1543, 2002

15 "National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report" 106 : 3143-3421, 2002

16 Kassi E, "Metabolic syndrome: definitions and controversies" 9 : 48-, 2011

17 De Nunzio C, "Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy"

18 de Santana IA, "Metabolic syndrome in patients with prostate cancer" 126 : 274-278, 2008

19 Laukkanen JA, "Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study" 13 : 1646-1650, 2004

20 Ministry of Health and Welfare, "Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2009" National Cancer Center 2011

21 Renehan AG, "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis" 363 : 1346-1353, 2004

22 윤철용, "Higher Body Mass Index Is Associated With Lower Risk of Prostate Cancer Detection Via Multi (>= 12)-Core Prostate Biopsy in Korean Men" ELSEVIER SCIENCE INC 76 : 1063-1066, 201011

23 Hammarsten J, "Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer" 13 : 47-55, 2004

24 Freedland SJ, "Body mass index as a predictor of prostate cancer: development versus detection on biopsy" 66 : 108-113, 2005

25 Freedland SJ, "Are findings from studies of obesity and prostate cancer really in conflict?" 17 : 5-9, 2006